Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Qu Ang

Peking University Third Hospital, China

Title: Preliminary results of nimotuzumab plus concurrent IMRT and chemotherapy on cervical cancer

Biography

Biography: Qu Ang

Abstract

Objective: To evaluate the safety and effi cacy of nimotuzumab plus concurrent intensity-modulated radiation therapy (IMRT)
and chemotherapy of unresectable cervical cancer.
Methods: From December 2013 to February 2017, 34 patients with cervical cancer on stage (FIGO) IB2-IVB were received
concurrent chemoradiotherapy plus nimotuzumab. Th e prescription dose of radiation was 50.4 Gy/28f on pelvic fi eld with or
with not extended fi eld radiation. An additional 30-36 Gy to Point A were delivered with high-dose-rate techniques. Cisplatin
of 40 mg/m2 and nimotuzumab of 200mg were infused intravenously once weekly during RT for 6 weeks. Th e main outcome
measure was toxicity evaluated by CTCAE 4.0. Secondary outcome measure was short-term outcome evaluated by RESIST1.1.
Result: Th e median of followed up time was 23.4 months (8.3-45.5 months). Almost all patients were local advantaged
cancer except 2 patients with distant metastases. All patients received external radiotherapy. 2 patients were not treated with
brachytherapy. 6 patients failed to fi nish radiotherapy within 56 days. All of 34 patients received concurrent treatment with
nimotuzumab for 6 times. 2 patients refused chemotherapy. Th ere was no life-threatening toxicity. Grade 1/2 of nausea,
vomiting and diarrhea were 70.6% (24/34), 32.4% (11/34) and 52.9% (18/34), respectively. Grade 3 of leucopenia, granulopenia,
thrombocytopenia and anemia were 52.9% (18/34), 17.6% (6/34), 14.7% (5/34), and 11.8% (4/34) respectively. Grade 3 of
nausea and vomiting were 8.8% (3/34) and 2.9% (1/34), respectively. No grade 3 of anorectal infl ammation. Rectovaginal
fi stula was observed in one case 6 months aft er radiotherapy, and operation was performed. Surgical treatment of intestinal
obstruction was performed in one case. 2 cases got vaginal stenosis. Th e objective response rate was 100%. Complete response
was achieved in 29 cases (85.3%) and partial response in 5 cases (14.7%).
Conclusion: Nimotuzumab plus concurrent IMRT and chemotherapy may represent an eff ective and well-tolerated treatment
in patients with unresectable cervical cancer.